May 6, 2024 — Elekta announced the acquisition of Philips Healthcare’s Pinnacle Treatment Planning System (TPS) patent portfolio. This strategic move bolsters Elekta’s position in treatment planning and underscores its commitment to being the innovation leader in radiation therapy.
Elekta and Philips have reached an agreement to transfer Philips’ patent portfolio in the radiation oncology treatment planning domain to Elekta, unlocking further innovations in radiation therapy treatment planning and workflow optimization. By integrating the technologies covered by the acquired patent portfolio, Elekta and Philips aim to offer a seamless and best-in-class transition for existing Pinnacle users to Elekta ONE Planning, including data conversion services, showcased at the upcoming ESTRO event.
In June 2021, Elekta and Philips announced their long-term strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions, from CT and MR simulation to treatment planning, preparation and delivery.
Maurits Wolleswinkel, President, Linac and Software Solutions at Elekta, said: “Thanks to continued investments over the years, our treatment planning system supports both Elekta and non-Elekta devices, including proton therapy, making Elekta ONE Planning one of the most competitive solutions in the market. At ESTRO, we will unveil exciting new capabilities, including novel scripting elements inspired by Pinnacle, demonstrating Elekta ONE’s competitive advantage.”
Martijn Hartjes, Business Leader Clinical Informatics at Philips, added: “We are pleased that we can continue to support our customers with leading solutions in radiation oncology. This is a logical next step in the strong long-term collaboration between Philips and Elekta in the radiotherapy domain to improve cancer care together.”
See a live demo of Elekta ONE, and how it will elegantly include Pinnacle-related technology, at ESTRO 2024, May 3-7 in Glasgow, UK at Elekta’s booth #440.
For more information: www.elekta.com
July 25, 2024 
